Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Work In Process (2017 - 2025)

Adma Biologics' Work In Process history spans 9 years, with the latest figure at $57.8 million for Q4 2025.

  • For Q4 2025, Work In Process fell 6.23% year-over-year to $57.8 million; the TTM value through Dec 2025 reached $57.8 million, down 6.23%, while the annual FY2025 figure was $57.8 million, 6.23% down from the prior year.
  • Work In Process reached $57.8 million in Q4 2025 per ADMA's latest filing, up from $44.5 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $62.1 million in Q1 2023 to a low of $43.2 million in Q2 2025.
  • Average Work In Process over 5 years is $53.1 million, with a median of $53.5 million recorded in 2024.
  • Peak YoY movement for Work In Process: skyrocketed 94.66% in 2021, then decreased 21.6% in 2025.
  • A 5-year view of Work In Process shows it stood at $59.0 million in 2021, then fell by 4.74% to $56.2 million in 2022, then decreased by 11.66% to $49.6 million in 2023, then grew by 24.22% to $61.6 million in 2024, then dropped by 6.23% to $57.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Work In Process are $57.8 million (Q4 2025), $44.5 million (Q3 2025), and $43.2 million (Q2 2025).